**Tables**

Table1: Results of gender-specific total psoas area, TPAI and HUAC

|  |  |
| --- | --- |
| Male Female | Sarcopenic Nonsarcopenic |
| Totalpsoasarea 17.37±4.3 10.05±2.5  TPAI (cm2/m2) 6.06±1.5 22±4  HUAC 22.44±4.08 18.16±5.3 | 12.5±4.9 15.91±5.02  4.8±1.5 5.64±1.67  15.95±4.57 22.93±3.56 |

*TPAI: total psoas area index, HUAC: Hounsfield unit average calculation*

Table 2. Patient characteristics

|  |  |  |  |
| --- | --- | --- | --- |
| Variables | Sarcopenic | Non-sarcopenic | Pvalue |
| Gender  Female  Male | 6(33.3)  12(66.7) | 17(32.7)  35(67.3) | 0.623 |
| Age (years)  <65 | 5(27.8) | 36(69.2) | **0.002** |
| >65 | 13(72.2) | 16(30.8) |
| ECOG  0 or 1  2 or 3 | 17(89.5)  2(10.5) | 44(86.3)  7(12.9) | 0.722 |
| Grade  1 or 2  3 | 14(77.8)  4(22.2) | 32(61.5)  20(38.5) | 0.211 |
| Tumor location  Right sided  Left sided | 5(27.8)  13(72.2) | 11(21.2)  41(78.8) | 0.536 |
| KRAS mutation  Yes  No | 6(33.3)  12(66.7) | 26(50)  26(50) | 0.221 |
| BMI (kg/m2)  Underweight (<18.5)Normal (18.5-24.9)  Overweight (25-29.9)Obese (≥30) | 0(0)  8(44.4)  8(44.4)  2(11.2) | 3(5.8)  28(53.8)  18(34.6)  3(5.8) | 0.564 |
| Liver metastasis  No  Yes | 3(16.7)  15(83.3) | 10(19.2)  42(80.8) | 0.558 |

BMI: Body mass index, ECOG: Eastern Cooperative Oncology Group performance status, KRAS: Kirsten rat sarcoma viral oncogene homolog

Table 3: Effects of clinicopathologic factors and sarcopenia on survival: univariate analysis

|  |  |  |  |
| --- | --- | --- | --- |
| Sarcopenia  presentvsnone | 0.511 | 0.288-0.907 | 0.022 |
| Age (years)  <65 vs ≥65 | 1.420 | 0.836-2.414 | 0.195 |
| ECOG  0 or 1vs2 or 3 | 0.946 | 0.670-1.336 | 0.751 |
| Gender  Femalevsmen | 0.860 | 0.488-1.515 | 0.602 |
| Liver metastasis  presentvsnone | 1.023 | 0.527-1.986 | 0.946 |
| KRAS mutation  Mutantvs wild | 1.061 | 0.626-1.798 | 0.827 |
| CEA  <5 vs ≥5 | 1.526 | 0.847-2.744 | 0.159 |
| Tumor localization  Right vsleft-sided | 1.227 | 0.657-2.291 | 0.520 |

CEA: Carcinoembryonic antigen, ECOG: Eastern Cooperative Oncology Group performance status, KRAS: Kirsten rat sarcoma viral oncogene homolog